Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AARD Aardvark Therapeutics	$11.12 +6.5%	$9.20	$4.88 ▼ $19.58	$241.26M	N/A	105,873 shs	22,738 shs
RNAC Cartesian Therapeutics	$9.97 +4.3%	$11.04	$8.46 ▼ $41.87	$258.81M	0.51	114,776 shs	117,461 shs
SGTX Sigilon Therapeutics	$22.47	$22.02	$3.77 ▼ $28.00	$56.40M	4.12	62,902 shs	N/A
TNGX Tango Therapeutics	$2.54 +14.2%	$1.50	$1.03 ▼ $12.02	$274.78M	1.02	1.33 million shs	3.79 million shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AARD Aardvark Therapeutics	0.00%	+0.19%	-18.20%	-17.36%	+1,051,999,900.00%
RNAC Cartesian Therapeutics	0.00%	+4.37%	-24.72%	-45.37%	-72.47%
SGTX Sigilon Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
TNGX Tango Therapeutics	0.00%	+18.48%	+44.37%	+14.74%	-68.50%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AARD Aardvark Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RNAC Cartesian Therapeutics	2.2634 of 5 stars	3.4	1.0	0.0	0.0	3.5	3.3	0.0
SGTX Sigilon Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TNGX Tango Therapeutics	1.8572 of 5 stars	3.5	1.0	0.0	0.0	3.3	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AARD Aardvark Therapeutics	3.00	Buy	$31.25	181.03% Upside
RNAC Cartesian Therapeutics	2.71	Moderate Buy	$43.00	331.21% Upside
SGTX Sigilon Therapeutics	0.00	N/A	N/A	N/A
TNGX Tango Therapeutics	3.00	Buy	$12.20	381.26% Upside

Current Analyst Ratings Breakdown

Latest SGTX, RNAC, AARD, and TNGX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/15/2025	AARD Aardvark Therapeutics	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$21.00 ➝ $20.00
5/8/2025	RNAC Cartesian Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$41.00 ➝ $40.00
4/14/2025	TNGX Tango Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00 ➝ $13.00
4/9/2025	RNAC Cartesian Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$41.00 ➝ $41.00
4/9/2025	RNAC Cartesian Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00 ➝ $40.00
4/1/2025	AARD Aardvark Therapeutics	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$21.00 ➝ $21.00
4/1/2025	AARD Aardvark Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$50.00 ➝ $50.00
3/27/2025	AARD Aardvark Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$22.00 ➝ $26.00
3/14/2025	RNAC Cartesian Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$45.00 ➝ $40.00
3/13/2025	RNAC Cartesian Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$41.00 ➝ $41.00
3/10/2025	AARD Aardvark Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$29.00

(Data available from 6/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AARD Aardvark Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A
RNAC Cartesian Therapeutics	$34.17M	7.57	N/A	N/A	($82.38) per share	-0.12
SGTX Sigilon Therapeutics	$12.94M	4.36	N/A	N/A	$15.68 per share	1.43
TNGX Tango Therapeutics	$40.99M	6.70	N/A	N/A	$2.48 per share	1.02

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AARD Aardvark Therapeutics	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
RNAC Cartesian Therapeutics	-$219.71M	-$52.83	N/A	N/A	N/A	-510.72%	N/A	-6.03%	8/14/2025 (Estimated)
SGTX Sigilon Therapeutics	-$43.56M	-$12.23	N/A	N/A	N/A	-171.29%	-83.07%	-38.17%	N/A
TNGX Tango Therapeutics	-$101.74M	-$1.22	N/A	N/A	N/A	-284.42%	-49.64%	-32.00%	8/6/2025 (Estimated)

Latest SGTX, RNAC, AARD, and TNGX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	N/A	AARD Aardvark Therapeutics	-$0.70	-$0.71	-$0.01	-$0.71	N/A	N/A
5/12/2025	Q1 2025	TNGX Tango Therapeutics	-$0.34	-$0.36	-$0.02	-$0.36	$6.73 million	$5.39 million
5/8/2025	Q1 2025	RNAC Cartesian Therapeutics	-$0.61	-$0.68	-$0.07	-$0.68	$0.69 million	$1.10 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AARD Aardvark Therapeutics	N/A	N/A	N/A	N/A	N/A
RNAC Cartesian Therapeutics	N/A	N/A	N/A	N/A	N/A
SGTX Sigilon Therapeutics	N/A	N/A	N/A	N/A	N/A
TNGX Tango Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AARD Aardvark Therapeutics	N/A	N/A	N/A
RNAC Cartesian Therapeutics	N/A	10.70	10.70
SGTX Sigilon Therapeutics	N/A	1.78	1.78
TNGX Tango Therapeutics	N/A	8.00	8.00

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AARD Aardvark Therapeutics	N/A
RNAC Cartesian Therapeutics	86.95%
SGTX Sigilon Therapeutics	N/A
TNGX Tango Therapeutics	78.99%

Insider Ownership

Company	Insider Ownership
AARD Aardvark Therapeutics	N/A
RNAC Cartesian Therapeutics	57.90%
SGTX Sigilon Therapeutics	6.50%
TNGX Tango Therapeutics	6.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AARD Aardvark Therapeutics	18	21.70 million	N/A	N/A
RNAC Cartesian Therapeutics	64	25.95 million	10.70 million	Optionable
SGTX Sigilon Therapeutics	62	2.51 million	2.35 million	Not Optionable
TNGX Tango Therapeutics	90	108.39 million	100.65 million	Optionable

SGTX, RNAC, AARD, and TNGX Headlines

Recent News About These Companies

Woodline Partners LP Takes Position in Tango Therapeutics, Inc. (NASDAQ:TNGX)

May 28, 2025 | marketbeat.com

Tango Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference

May 27, 2025 | finance.yahoo.com

Tango Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference

May 27, 2025 | globenewswire.com

Tango Therapeutics starts trial for brain cancer drug

May 23, 2025 | uk.investing.com

Tango Therapeutics Announces First Patient Dosed in TNG456 Phase 1/2 Trial in Patients With MTAP-deleted Glioblastomas and Other Solid Tumors

May 21, 2025 | globenewswire.com

517,426 Shares in Tango Therapeutics, Inc. (NASDAQ:TNGX) Acquired by Jacobs Levy Equity Management Inc.

May 19, 2025 | marketbeat.com

Q2 EPS Estimate for Tango Therapeutics Increased by Analyst

May 17, 2025 | marketbeat.com

Dimensional Fund Advisors LP Purchases 302,087 Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX)

May 17, 2025 | marketbeat.com

Tango Therapeutics, Inc. (NASDAQ:TNGX) Just Reported Earnings, And Analysts Cut Their Target Price

May 16, 2025 | finance.yahoo.com

Orbimed Advisors LLC Takes Position in Tango Therapeutics, Inc. (NASDAQ:TNGX)

May 15, 2025 | marketbeat.com

Tango Therapeutics (NASDAQ:TNGX) Posts Earnings Results, Misses Estimates By $0.02 EPS

May 14, 2025 | marketbeat.com

Tango Therapeutics Reports Q1 2025 Financial Results and Updates on TNG462 and Pipeline Developments

May 14, 2025 | nasdaq.com

Tango Therapeutics, Inc.: Tango Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights

May 13, 2025 | finanznachrichten.de

Tango Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights

May 13, 2025 | finance.yahoo.com

Tango Therapeutics Extends Cash Runway Amid Clinical Progress

May 13, 2025 | tipranks.com

Tango Therapeutics, Inc. (TNGX) Reports Q1 Loss, Lags Revenue Estimates

May 12, 2025 | zacks.com

Tango Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights

May 12, 2025 | globenewswire.com

4,000,000 Shares in Tango Therapeutics, Inc. (NASDAQ:TNGX) Bought by Farallon Capital Management LLC

May 11, 2025 | marketbeat.com

Balyasny Asset Management L.P. Has $10.13 Million Position in Tango Therapeutics, Inc. (NASDAQ:TNGX)

May 11, 2025 | marketbeat.com

Tango Therapeutics, Inc. (NASDAQ:TNGX) Given Consensus Rating of "Buy" by Analysts

May 11, 2025 | marketbeat.com

Tango Therapeutics (TNGX) to Release Quarterly Earnings on Monday

May 7, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SGTX, RNAC, AARD, and TNGX Company Descriptions

Aardvark Therapeutics NASDAQ:AARD

$11.12 +0.68 (+6.51%)

As of 03:57 PM Eastern

Aardvark Therapeutics, Inc. operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.

Cartesian Therapeutics NASDAQ:RNAC

$9.97 +0.41 (+4.31%)

Closing price 03:59 PM Eastern

Extended Trading

$9.98 +0.01 (+0.13%)

As of 04:04 PM Eastern

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.

Sigilon Therapeutics NASDAQ:SGTX

Sigilon Therapeutics, Inc., a preclinical stage biotechnology company, develops functional cures for patients with acute and chronic diseases. Its lead product candidate is SIG-002 to replace islet cells for the treatment of type 1 diabetes; and SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-205, SIG-218, SIG-220, and SIG-005, which are to treat the non-neurological manifestations of mucopolysaccharidosis type 1; and SIG-207 is to treat of Fabry disease. Sigilon Therapeutics, Inc. has a research collaboration and license agreement with Eli Lilly and Company for the development and commercialization of SLTx product candidates for the treatment of Type 1 Diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Tango Therapeutics NASDAQ:TNGX

$2.54 +0.32 (+14.19%)

Closing price 03:59 PM Eastern

Extended Trading

$2.52 -0.01 (-0.39%)

As of 04:13 PM Eastern

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time